ArticleCellular signalling2026
Localization, trafficking, and signaling of trace amine-associated receptor 2 in mouse neuroblastoma cells.
Article in Cellular signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Trace amine-associated receptors (TAARs) are a family of G protein-coupled receptors increasingly recognized for their role in modulating neurotransmission. Among the TAAR isoforms, TAAR2 remains poorly understood despite growing appreciation of its involvement in neurological disorders. In this study, we characterized the subcellular localization and agonist-induced trafficking dynamics of TAAR2 in mouse Neuro-2a cells stably expressing N-terminal His-tagged TAAR2. Under basal conditions, immunocytochemical analysis revealed that TAAR2 was predominantly localized intracellularly. Upon stimulation with β-phenethylamine (β-PEA), a pan-TAAR agonist, TAAR2 underwent rapid and dynamic redistribution across subcellular compartments. Specifically, within 5 min, TAAR2 exited the endoplasmic reticulum (ER) and accumulated in the Golgi. By 10-20 min, its localization in the ER and Golgi returned to baseline, while TAAR2 slowly translocated to the plasma membrane, reaching peak surface expression at 20 min. Functional assays demonstrated that TAAR2 coupled to Gαi/o proteins, but not Gαs proteins, as evidenced by β-PEA-induced inhibition of forskolin-stimulated cAMP production. Notably, this inhibition became significant at 20 min of agonist treatment, coinciding with peak plasma membrane localization of TAAR2 following agonist treatment. Together, these findings establish a clear temporal link between TAAR2 trafficking and signaling, suggesting that subcellular localization is tightly coupled to receptor function. This study provides the first characterization of TAAR2's trafficking and signaling in a neuronal-like context, laying the groundwork for future investigations into its role in neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.